2. Search Result
Search Result
Results for "

Domain,

" in MedChemExpress (MCE) Product Catalog:

891

Inhibitors & Agonists

6

Screening Libraries

3

Fluorescent Dye

7

Biochemical Assay Reagents

173

Peptides

82

Inhibitory Antibodies

34

Natural
Products

430

Recombinant Proteins

25

Isotope-Labeled Compounds

85

Antibodies

2

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4998
    Chemotactic Domain of Elastin

    		Biochemical Assay Reagents Cancer
    Chemotactic Domain of Elastin is an elastin-derived peptide with chemotactic effects on certain tumor cells, such as M27 tumor cells. Chemotactic Domain of Elastin can be used in cancer research .
    Chemotactic Domain of Elastin
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-151577
    STAT3-SH2 domain inhibitor 1

    		STAT Apoptosis Cancer
    STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
    STAT3-SH2 domain inhibitor 1
  • HY-P2516
    Tau Peptide (275-305) (Repeat 2 domain)

    		Tau Protein Neurological Disease
    Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein .
    Tau Peptide (275-305) (Repeat 2 domain)
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable

    Hxk2VBD peptide, cell-permeable

    		 Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-P10521
    Apolipoprotein KV domain (67-77)

    		VEGFR Cancer
    Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
    Apolipoprotein KV domain (67-77)
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-P9802
    Anti-Spike-RBD Single Domain mAb

    SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody

    		 SARS-CoV Infection
    Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
    Anti-Spike-RBD Single Domain mAb
  • HY-P4924
    Tau Peptide (244-274) (Repeat 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (244-274) (Repeat 1 Domain) is aTau fragment.
    Tau Peptide (244-274) (Repeat 1 Domain)
  • HY-P4927
    Tau Peptide (245-274) (Repeat 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (245-274) (Repeat 1 Domain) is aTau fragment.
    Tau Peptide (245-274) (Repeat 1 Domain)
  • HY-P4966
    Tau Peptide (306-336) (Repeat 3 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (306-336) (Repeat 3 Domain) is aTau fragment.
    Tau Peptide (306-336) (Repeat 3 Domain)
  • HY-P4972
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is aTau fragment.
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain)
  • HY-P4977
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is aTau fragment.
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)
  • HY-P10316
    CaMKI(299-320)

    Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain

    		 CaMK Others
    CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
    CaMKI(299-320)
  • HY-146127
    Grb2 SH2 domain inhibitor 1

    		EGFR Others
    Grb2 SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
    Grb2 SH2 domain inhibitor 1
  • HY-P4933
    Tau Peptide (255-314) (Repeat 2 Domain) (human)

    		Tau Protein Others
    Tau Peptide (255-314) (Repeat 2 Domain) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
  • HY-146127A
    Grb2 SH2 domain inhibitor 1 TFA

    		Src Others
    Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
    Grb2 SH2 domain inhibitor 1 TFA
  • HY-P5904
    Caveolin-1 (82-101) amide (human, mouse, rat)

    Caveolin-1 scaffolding domain peptide

    		 c-Met/HGFR Others
    Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) inhibits tyrosine kinases .
    Caveolin-1 (82-101) amide (human, mouse, rat)
  • HY-P4110
    TAT-NSF222 Fusion Peptide

    		iGluR Metabolic Disease Inflammation/Immunology
    TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor .
    TAT-NSF222 Fusion Peptide
  • HY-W746708
    FK-565

    		NOD-like Receptor (NLR) Inflammation/Immunology
    FK-565 is a nucleotide oligomerization domain-1 (NOD1) ligand. FK-565 induces murine model with arteritis .
    FK-565
  • HY-12135
    Poloxipan

    		Polo-like Kinase (PLK) PIN1 STAT Cancer
    Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
    Poloxipan
  • HY-E70229
    Cyclooxygenase 1, sheep

    COX-1

    		 Endogenous Metabolite Metabolic Disease
    Cyclooxygenase 1, sheep (COX-1) is a 71 kDa membrane bound protein predominantly present in endoplasmic reticulum. Cyclooxygenase 1 has three domains, the epidermal growth factor (EGF) like domain, enzymatic and membrane binding domain. Cyclooxygenase 1 mediates prostaglandin synthesis and is modulated by anti-inflammatory nonsteroidal drugs .
    Cyclooxygenase 1, sheep
  • HY-124808
    IMM-01

    		Ras Apoptosis Cancer
    IMM-01 is a mammalian Diaphanous (mDia)-related formins agonist that inhibits DID-DAD (diaphanous inhibitory domain-diaphanous autoregulatory domain) binding with an IC50 of 140 nM. IMM-01 acts by disrupting the autoinhibitory bond between the DID and DAD domain and thus activates formins. IMM-01 shows anticancer effects .
    IMM-01
  • HY-104068
    Naphthol AS-E

    		Histone Acetyltransferase Epigenetic Reader Domain Cancer
    Naphthol AS-E is a potent and cell-permeable inhibitor of KIX-KID interaction. Naphthol AS-E directly binds to the KIX domain of CBP (Kd:8.6 μM), blocks the interaction between the KIX domain and the KID domain of CREB with IC50 of 2.26 μM. Naphthol AS-E can be used for cancer research.
    Naphthol AS-E
  • HY-P1985A
    Notch 1 TFA

    		Notch Cardiovascular Disease Cancer
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .
    Notch 1 TFA
  • HY-P99562
    Tidutamab

    XmAb-18087

    		 CD3 Cancer
    Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
    Tidutamab
  • HY-P3279
    EPQpYEEIPIYL
    1 Publications Verification

    		 Src Cancer
    EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .
    EPQpYEEIPIYL
  • HY-P5324
    Bad BH3 (mouse)

    		Bcl-2 Family Others
    Bad BH3 (mouse) is a biological active peptide. (This is a bcl-2 binding peptide. This peptide is derived from the BH3 domain (a death domain) of Bad, amino acid residues 140 to 165.)
    Bad BH3 (mouse)
  • HY-138283
    MR837
    1 Publications Verification

    		 Histone Methyltransferase Cancer
    MR837 is an inhibitor of NSD2-PWWP1. MR837 can bind with human nuclear receptor binding SET domain protein 2 (PWWP domain) .
    MR837
  • HY-13638
    GDC-0152
    10+ Cited Publications

    		 IAP Cancer
    GDC-0152 is a potent IAPs inhibitor, and binds to the BIR3 domains of XIAP, cIAP1, cIAP2 and the BIR domain of ML-IAP with Ki values of 28 nM, 17 nM, 43 nM and 14 nM, respectively.
    GDC-0152
  • HY-150269
    RS5517

    		Na+/H+ Exchanger (NHE) Cancer
    RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer .
    RS5517
  • HY-12315
    N-Oxalylglycine

    N-Oxaloglycine

    		 Histone Demethylase HIF/HIF Prolyl-Hydroxylase Cancer
    N-Oxalylglycine (N-Oxaloglycine) is a Jumonji C-domain-containing histone lysine demethylase inhibitor. N-Oxalylglycine inhibits JMJD2A, JMJD2C and JMJD2D. N-Oxalylglycine also inhibits HIF prolylhydroxylase domain-1 (PHD-1) and PHD-2, with an IC50 of 2.1 μM and 5.6 μM, respectively .
    N-Oxalylglycine
  • HY-19820
    NSC45586

    		Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 can activate AKT in neurons .
    NSC45586
  • HY-19820A
    NSC45586 sodium

    		Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 sodium is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 sodium targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 sodium can activate AKT in neurons .
    NSC45586 sodium
  • HY-P99306
    Modotuximab

    DS 1024

    		 EGFR Cancer
    Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
    Modotuximab
  • HY-P99830
    Conbercept

    KH902

    		 VEGFR Cardiovascular Disease
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .
    Conbercept
  • HY-P10543
    SMRT peptide

    		BCL6 Cancer
    SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
    SMRT peptide
  • HY-150536
    EP39

    		HIV HIV Protease Infection
    EP39 is a potent HIV-1 maturation inhibitor. EP39 interacts with the SP1 domain of Gag. EP39 decreases the dynamics of CA-SP1 junction, by binding to the QVT motif of the SP1 domain, and perturbs the natural coil-helix equilibrium on both sides of the SP1 domain by stabilizing the transient alpha helical structure. EP39 acts by arresting maturation of HIV-1 thereby blocking its infectivity .
    EP39
  • HY-145416
    G247

    		Bacterial Infection
    G247 is a specific MsbA inhibitor. G247 acts as a transmembrane domains (TMDs) wedge, symmetrically increasing nucleotide-binding domains (NBDs) separation and preventing conformational transition of MsbA. G247 suppresses ATPase activity by increasing inter-NBD distance .
    G247
  • HY-P99283
    Concizumab
    1 Publications Verification

    NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody

    		 Factor Xa Others
    Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
    Concizumab
  • HY-P5341
    Bik BH3

    		Bcl-2 Family Others
    Bik BH3 is a biological active peptide. (BH3 domain of BIK)
    Bik BH3
  • HY-P5342
    Hrk BH3

    		Bcl-2 Family Others
    Hrk BH3 is a biological active peptide. (BH3 domain of Hrk)
    Hrk BH3
  • HY-151634
    Syk-IN-6

    		Syk STAT ERK Cancer
    Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML) .
    Syk-IN-6
  • HY-157393
    BET bromodomain inhibitor 4

    		Epigenetic Reader Domain Cancer
    BET bromodomain inhibitor 4 (example 7) is an inhibitor of the BET bromodomain domain .
    BET bromodomain inhibitor 4
  • HY-115671
    KLH45b

    		Phosphatase Neurological Disease
    KLH45b is an inhibitor of DDHD2 (DDHD domain containing 2) .
    KLH45b
  • HY-P5328
    Noxa A BH3

    		NADPH Oxidase Others
    Noxa A BH3 is a biological active peptide. (BH3 domain of Noxa protein)
    Noxa A BH3
  • HY-P4076
    MPG peptides, Pβ

    		HIV Cancer
    MPG peptides, Pβ is a primary amphiphilic peptide consisting of three domains .
    MPG peptides, Pβ
  • HY-P1816
    Fibronectin CS1 Peptide

    		Integrin Cancer
    The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models .
    Fibronectin CS1 Peptide
  • HY-125292
    NV03

    		Histone Methyltransferase Ligands for E3 Ligase Cancer
    NV03 is a potent and selective antagonist of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)- H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a Kd of 2.4 μM. NV03 has anticancer activity .
    NV03
  • HY-P5329
    r8-Gly-Noxa A BH3

    		NADPH Oxidase Others
    r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)
    r8-Gly-Noxa A BH3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: